3 completed, 2 not yet recruiting, 2 terminated, 1 recruiting. 4 Phase 1, 3 Phase 2, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Non-Small Cell Lung Carcinoma (NSCLC): new trials by email Literature Review of Non-Small Cell Lung Carcinoma (NSCLC) trials Research Report on Non-Small Cell Lung Carcinoma (NSCLC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. Blood sampling, Tumor biopsies for biobank establishment (optional) - Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma | Phase 4 | Not yet recruiting | Centre Antoine Lacassagne | 110 | 2026-10-01 | 2026-09-15 |
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. SCTB14, Pembrolizumab - Non-Small Cell Lung Carcinoma (NSCLC) | Phase 3 | Recruiting | Sinocelltech Ltd. | 246 | 2025-12-30 | 2026-01-23 |
| A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases Capmatinib - Non-small Cell Lung Carcinoma (NSCLC) | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2020-11-11 | 2020-12-03 | |
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Selinexor 100 mg, Docetaxel, Pembrolizumab - Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Completed | Karyopharm Therapeutics Inc | 80 | 2020-02-09 | 2026-10-09 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis LITT + Pembrolizumab - Melanoma, Non-small Cell Lung Carcinoma (NSCLC) | Phase 1 | Terminated | University of Florida | 10 | 2020-01-10 | 2023-12-27 |
| Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care Survey - Non-Small Cell Lung Carcinoma (NSCLC) | Not applicable | Completed | Abramson Cancer Center at Penn Medicine | 120 | 2015-03-01 | 2020-02-06 |
| Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) CM-24 (MK-6018), Pembrolizumab (MK-3475) - Non-small Cell Lung Carcinoma (NSCLC), Melanoma | Phase 1 | Terminated | Famewave Ltd. | 27 | 2015-02-01 | 2020-08-27 |
| ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer ZD1839 (Iressa), Thoracic Radiotherapy - Non-Small Cell Lung Carcinoma (NSCLC) | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 13 | 2003-12-01 | 2025-05-04 |
Carcinoma, Non-Small-Cell Lung (9) · Colorectal Neoplasms (3) · Stomach Neoplasms (3) · Carcinoma, Transitional Cell (2) · Melanoma (2) · Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Endometrial Neoplasms (1)
Bronchial Neoplasms (9) · Carcinoma, Bronchogenic (9) · Lung Diseases (9) · Neoplasms by Site (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9) · Thoracic Neoplasms (9) · Lung Neoplasms (8) · Neoplasms (7) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4)
pembrolizumab (4) · Blood Specimen Collection (1) · Docetaxel (1) · Gefitinib (1) · IFL protocol (1) · Surveys and Questionnaires (1) · capmatinib (1) · selinexor (1)
Abramson Cancer Center at Penn Medicine (1) · Centre Antoine Lacassagne (1) · Famewave Ltd. (1) · Haihua Yuan (1) · Karyopharm Therapeutics Inc (1) · Novartis Pharmaceuticals (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Sinocelltech Ltd. (1) · University of Florida (1)
United States (4) · Israel (2) · China (1)
Joshua Bauml, MD (1) · Maria Werner-Wasik, MD (1) · Maryam Rahman, MD (1)